Actively Recruiting
Phase I Study of HLX3901 Given by IV Infusion in Adults With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma
Led by Shanghai Henlius Biotech · Updated on 2026-07-08
138
Participants Needed
2
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying HLX3901 in an open-label, first-in-human phase I clinical trial involving patients with advanced small cell lung cancer SCLC or neuroendocrine carcinoma NEC. The study aims to evaluate the safety, tolerability, and how the drug behaves in the body, focusing on patients who have experienced intolerance, recurrence, or disease progression after prior treatments. The study has two parts Phase Ia uses dose escalation and backfill cohorts where patients receive HLX3901 via intravenous infusion at increasing doses, observing dose-limiting toxicities over 4 weeks. Phase Ib expands the dose to confirm safety and efficacy of HLX3901 monotherapy in selected groups based on Phase Ia data. Participants receive the recommended Phase 2 dose RP2D identified during dose escalation. Participants will undergo screening, treatment cycles of 4 weeks, and monitoring of side effects and tumor response using objective response rates and survival measures over approximately 24 months. Safety reviews guide dosing decisions, and tumor tissue will be collected to test for DLL3 expression. The study involves regular assessments including laboratory tests and imaging to monitor health and treatment effects throughout participation, which can last up to about two years.
CONDITIONS
Brief Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here